| Author | Marin, Anelis Maria | |
| Author | Wosniaki, Denise Kusma | |
| Author | Sanchuki, Heloisa Bruna Soligo | |
| Author | Munhoz, Eduardo Cilião | |
| Author | Nardin, Jeanine Marie | |
| Author | Soares, Gabriela Silva | |
| Author | Espinace, Dhienifer Caroline | |
| Author | Farias, João Samuel de Holanda | |
| Author | Veroneze, Bruna | |
| Author | Becker, Luiz Felipe | |
| Author | Costa, Guilherme Lima | |
| Author | Beltrame, Olair Carlos | |
| Author | Oliveira, Jaqueline Carvalho de | |
| Author | Cambri, Geison | |
| Author | Zanette, Dalila Lucíola | |
| Author | Aoki, Mateus Nóbrega | |
| Access date | 2023-07-24T19:51:02Z | |
| Available date | 2023-07-24T19:51:02Z | |
| Document date | 2023 | |
| Citation | MARIN, Anelis Maria et al. Molecular BCR::ABL1 quantification and ABL1 mutation detection as essential tools for the clinical management of chronic myeloid leukemia patients: results from a Brazilian single-center study. Viruses, v. 285, n. 104955, p. 1-13, 2023. | en_US |
| ISSN | 1422-0067 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/59733 | |
| Language | por | en_US |
| Publisher | MDPI | en_US |
| Rights | open access | en_US |
| Title | Molecular BCR::ABL1 quantification and ABL1 mutation detection as essential tools for the clinical management of chronic myeloid leukemia patients: results from a Brazilian single-center study | en_US |
| Type | Article | en_US |
| DOI | 10.3390/ijms241210118 | |
| Abstract | Chronic myeloid leukemia (CML) is a well-characterized oncological disease in which virtually all patients possess a translocation (9;22) that generates the tyrosine kinase BCR::ABL1 protein. This translocation represents one of the milestones in molecular oncology in terms of both diagnostic and prognostic evaluations. The molecular detection of the BCR::ABL1 transcription is a required factor for CML diagnosis, and its molecular quantification is essential for assessing treatment options and clinical approaches. In the CML molecular context, point mutations on the ABL1 gene are also a challenge for clinical guidelines because several mutations are responsible for tyrosine kinase inhibitor resistance, indicating that a change may be necessary in the treatment protocol. So far, the European LeukemiaNet and the National Comprehensive Cancer Network (NCCN) have presented international guidelines on CML molecular approaches, especially those related to BCR::ABL1 expression. In this study, we show almost three years’ worth of data regarding the clinical treatment of CML patients at the Erasto Gaertner Hospital, Curitiba, Brazil. These data primarily comprise 155 patients and 532 clinical samples. BCR::ABL1 quantification by a duplexone-step RT-qPCR and ABL1 mutations detection were conducted. Furthermore, digital PCR for both BCR::ABL1 expression and ABL1 mutations were conducted in a sub-cohort. This manuscript describes and discusses the clinical importance and relevance of molecular biology testing in Brazilian CML patients, demonstrating its cost-effectiveness | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Hospital Erasto Gaertner. Curitiba, PR, Brasil. | en_US |
| Affilliation | Universidade Federal do Paraná. Departamento de Genética. Curitiba, PR, Brasil. | en_US |
| Affilliation | Instituto de Biologia Molecular do Paraná. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciencias e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil. | en_US |
| Subject | Fusion Proteins, bcr-abl | en_US |
| Subject | ABL1 mutation | en_US |
| Subject | Leukemia, Myeloid, Chronic-Phase | en_US |
| Subject | Prognosis | en_US |
| Subject in Spanish | Proteínas de Fusión bcr-abl | en_US |
| Subject in Spanish | Leucemia Mieloide de Fase Crónica | en_US |
| Subject in Spanish | Pronóstico | en_US |
| Subject in French | Protéines de fusion bcr-abl | en_US |
| Subject in French | Leucémie myéloïde en phase chronique | en_US |
| Subject in French | Pronostic | en_US |
| DeCS | Proteínas de Fusão bcr-abl | en_US |
| DeCS | Leucemia Mieloide de Fase Crônica | en_US |
| DeCS | Prognóstico | en_US |
